Literature DB >> 31069529

Multi-gene testing in neurological disorders showed an improved diagnostic yield: data from over 1000 Indian patients.

Aparna Ganapathy1, Avshesh Mishra1, Megha Rani Soni1, Priyanka Kumar1, Mukunth Sadagopan1, Anil Vittal Kanthi1, Irene Rosetta Pia Patric1, Sobha George1, Aparajit Sridharan1, T C Thyagarajan1, S L Aswathy1, H K Vidya1, Swathi M Chinnappa1, Swetha Nayanala1, Manasa B Prakash1, Vijayashree G Raghavendrachar1, Minothi Parulekar1, Vykuntaraju K Gowda2, Sheela Nampoothiri3, Ramshekhar N Menon4, Divya Pachat5, Vrajesh Udani6, Neeta Naik7, Mahesh Kamate8, A Radha Rama Devi9, P A Mohammed Kunju10, Mohandas Nair11, Anaita Udwadia Hegde12, M Pradeep Kumar13, Soumya Sundaram4, Preetha Tilak14, Ratna D Puri15, Krati Shah16, Jayesh Sheth17, Qurratulain Hasan18, Frenny Sheth17, Pooja Agrawal1, Shanmukh Katragadda1, Vamsi Veeramachaneni1, Vijay Chandru1,19, Ramesh Hariharan1,19, Ashraf U Mannan20.   

Abstract

BACKGROUND: Neurological disorders are clinically heterogeneous group of disorders and are major causes of disability and death. Several of these disorders are caused due to genetic aberration. A precise and confirmatory diagnosis in the patients in a timely manner is essential for appropriate therapeutic and management strategies. Due to the complexity of the clinical presentations across various neurological disorders, arriving at an accurate diagnosis remains a challenge.
METHODS: We sequenced 1012 unrelated patients from India with suspected neurological disorders, using TruSight One panel. Genetic variations were identified using the Strand NGS software and interpreted using the StrandOmics platform.
RESULTS: We were able to detect mutations in 197 genes in 405 (40%) cases and 178 mutations were novel. The highest diagnostic rate was observed among patients with muscular dystrophy (64%) followed by leukodystrophy and ataxia (43%, each). In our cohort, 26% of the patients who received definitive diagnosis were primarily referred with complex neurological phenotypes with no suggestive diagnosis. In terms of mutations types, 62.8% were truncating and in addition, 13.4% were structural variants, which are also likely to cause loss of function.
CONCLUSION: In our study, we observed an improved performance of multi-gene panel testing, with an overall diagnostic yield of 40%. Furthermore, we show that NGS (next-generation sequencing)-based testing is comprehensive and can detect all types of variants including structural variants. It can be considered as a single-platform genetic test for neurological disorders that can provide a swift and definitive diagnosis in a cost-effective manner.

Entities:  

Keywords:  Genetic testing; Multi-gene panel; Neurological disorders; Next-generation sequencing

Mesh:

Year:  2019        PMID: 31069529     DOI: 10.1007/s00415-019-09358-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  36 in total

Review 1.  Genetic testing in neurological diseases.

Authors:  Saskia Biskup; Thomas Gasser
Journal:  J Neurol       Date:  2012-05-23       Impact factor: 4.849

Review 2.  Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies.

Authors:  David T Miller; Margaret P Adam; Swaroop Aradhya; Leslie G Biesecker; Arthur R Brothman; Nigel P Carter; Deanna M Church; John A Crolla; Evan E Eichler; Charles J Epstein; W Andrew Faucett; Lars Feuk; Jan M Friedman; Ada Hamosh; Laird Jackson; Erin B Kaminsky; Klaas Kok; Ian D Krantz; Robert M Kuhn; Charles Lee; James M Ostell; Carla Rosenberg; Stephen W Scherer; Nancy B Spinner; Dimitri J Stavropoulos; James H Tepperberg; Erik C Thorland; Joris R Vermeesch; Darrel J Waggoner; Michael S Watson; Christa Lese Martin; David H Ledbetter
Journal:  Am J Hum Genet       Date:  2010-05-14       Impact factor: 11.025

Review 3.  Epidemiology of neurological disorders in India: review of background, prevalence and incidence of epilepsy, stroke, Parkinson's disease and tremors.

Authors:  M Gourie-Devi
Journal:  Neurol India       Date:  2014 Nov-Dec       Impact factor: 2.117

4.  Molecular findings among patients referred for clinical whole-exome sequencing.

Authors:  Yaping Yang; Donna M Muzny; Fan Xia; Zhiyv Niu; Richard Person; Yan Ding; Patricia Ward; Alicia Braxton; Min Wang; Christian Buhay; Narayanan Veeraraghavan; Alicia Hawes; Theodore Chiang; Magalie Leduc; Joke Beuten; Jing Zhang; Weimin He; Jennifer Scull; Alecia Willis; Megan Landsverk; William J Craigen; Mir Reza Bekheirnia; Asbjorg Stray-Pedersen; Pengfei Liu; Shu Wen; Wendy Alcaraz; Hong Cui; Magdalena Walkiewicz; Jeffrey Reid; Matthew Bainbridge; Ankita Patel; Eric Boerwinkle; Arthur L Beaudet; James R Lupski; Sharon E Plon; Richard A Gibbs; Christine M Eng
Journal:  JAMA       Date:  2014-11-12       Impact factor: 56.272

5.  Clinical exome sequencing for genetic identification of rare Mendelian disorders.

Authors:  Hane Lee; Joshua L Deignan; Naghmeh Dorrani; Samuel P Strom; Sibel Kantarci; Fabiola Quintero-Rivera; Kingshuk Das; Traci Toy; Bret Harry; Michael Yourshaw; Michelle Fox; Brent L Fogel; Julian A Martinez-Agosto; Derek A Wong; Vivian Y Chang; Perry B Shieh; Christina G S Palmer; Katrina M Dipple; Wayne W Grody; Eric Vilain; Stanley F Nelson
Journal:  JAMA       Date:  2014-11-12       Impact factor: 56.272

6.  Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions.

Authors:  Kelly D Farwell; Layla Shahmirzadi; Dima El-Khechen; Zöe Powis; Elizabeth C Chao; Brigette Tippin Davis; Ruth M Baxter; Wenqi Zeng; Cameron Mroske; Melissa C Parra; Stephanie K Gandomi; Ira Lu; Xiang Li; Hong Lu; Hsiao-Mei Lu; David Salvador; David Ruble; Monica Lao; Soren Fischbach; Jennifer Wen; Shela Lee; Aaron Elliott; Charles L M Dunlop; Sha Tang
Journal:  Genet Med       Date:  2014-11-13       Impact factor: 8.822

Review 7.  Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing.

Authors:  Yuan Xue; Arunkanth Ankala; William R Wilcox; Madhuri R Hegde
Journal:  Genet Med       Date:  2014-09-18       Impact factor: 8.822

8.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

9.  Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1.

Authors:  Gemma L Carvill; Sinéad B Heavin; Simone C Yendle; Jacinta M McMahon; Brian J O'Roak; Joseph Cook; Adiba Khan; Michael O Dorschner; Molly Weaver; Sophie Calvert; Stephen Malone; Geoffrey Wallace; Thorsten Stanley; Ann M E Bye; Andrew Bleasel; Katherine B Howell; Sara Kivity; Mark T Mackay; Victoria Rodriguez-Casero; Richard Webster; Amos Korczyn; Zaid Afawi; Nathanel Zelnick; Tally Lerman-Sagie; Dorit Lev; Rikke S Møller; Deepak Gill; Danielle M Andrade; Jeremy L Freeman; Lynette G Sadleir; Jay Shendure; Samuel F Berkovic; Ingrid E Scheffer; Heather C Mefford
Journal:  Nat Genet       Date:  2013-05-26       Impact factor: 38.330

10.  Assessing the necessity of confirmatory testing for exome-sequencing results in a clinical molecular diagnostic laboratory.

Authors:  Samuel P Strom; Hane Lee; Kingshuk Das; Eric Vilain; Stanley F Nelson; Wayne W Grody; Joshua L Deignan
Journal:  Genet Med       Date:  2014-01-09       Impact factor: 8.822

View more
  5 in total

1.  Clinical, genetic profile and disease progression of sarcoglycanopathies in a large cohort from India: high prevalence of SGCB c.544A > C.

Authors:  Mainak Bardhan; Ram Murthy Anjanappa; Kiran Polavarapu; Veeramani Preethish-Kumar; Seena Vengalil; Saraswati Nashi; Shamita Sanga; Hansashree Padmanabh; Ravi Kiran Valasani; Vikas Nishadham; Muddasu Keerthipriya; Thenral S Geetha; Vedam Ramprasad; Gautham Arunachal; Priya Treesa Thomas; Moulinath Acharya; Atchayaram Nalini
Journal:  Neurogenetics       Date:  2022-04-13       Impact factor: 3.017

2.  Validation of whole genome sequencing from dried blood spots.

Authors:  Pooja Agrawal; Shanmukh Katragadda; Arun K Hariharan; Vijayashree Gauribidanur Raghavendrachar; Arunika Agarwal; Rashmi Dayalu; Disha Awasthy; Sanjay C Sharma; Yasodha Kannan Sivasamy; P Lakshmana; Ashwini Shanmugam; Vamsi Veeramachaneni; Vaijayanti Gupta; B P Vani; Lekha Subaiya; T S Syamala; Ramesh Hariharan; Vijay Chandru; David E Bloom
Journal:  BMC Med Genomics       Date:  2021-04-20       Impact factor: 3.063

3.  First Two Case Reports of Becker's Type Myotonia Congenita in Colombia: Clinical and Genetic Features.

Authors:  Jorge Andres Olave-Rodriguez; Francisco Javier Bonilla-Escobar; Estephania Candelo; Lisa Ximena Rodriguez-Rojas
Journal:  Appl Clin Genet       Date:  2021-12-16

4.  Molecular Diagnosis of Muscular Dystrophy Patients in Western Indian Population: A Comprehensive Mutation Analysis Using Amplicon Sequencing.

Authors:  Komal M Patel; Arpan D Bhatt; Krati Shah; Bhargav N Waghela; Ramesh J Pandit; Harsh Sheth; Chaitanya G Joshi; Madhvi N Joshi
Journal:  Front Genet       Date:  2021-12-03       Impact factor: 4.599

Review 5.  Phosphoinositides: Regulators of Nervous System Function in Health and Disease.

Authors:  Padinjat Raghu; Annu Joseph; Harini Krishnan; Pramod Singh; Sankhanil Saha
Journal:  Front Mol Neurosci       Date:  2019-08-23       Impact factor: 5.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.